Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
2007-07-10
2007-07-10
Haddad, Maher M. (Department: 1644)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
C530S402000
Reexamination Certificate
active
11080026
ABSTRACT:
The present invention provides a method for stabilizing a protein in a desired conformation by introducing at least one disulfide bond into the polypeptide. Computational design is used to identify positions where cysteine residues can be introduced to form a disulfide bond in only one protein conformation, and therefore lock the protein in a given conformation. Accordingly, antibody and small molecule therapeutics are selected that are specific for the desired protein conformation.The invention also provides modified integrin I-domain polypeptides that are stabilized in a desired conformation. The invention further provides screening assays and therapeutic methods utilizing the modified integrin I-domains of the invention.
REFERENCES:
patent: 5284931 (1994-02-01), Springer et al.
patent: 5288854 (1994-02-01), Diamond et al.
patent: 5395929 (1995-03-01), Corbi et al.
patent: 5460945 (1995-10-01), Springer et al.
patent: 5475091 (1995-12-01), Springer et al.
patent: 5489533 (1996-02-01), Springer et al.
patent: 5512660 (1996-04-01), Springer et al.
patent: 5514555 (1996-05-01), Springer et al.
patent: 5565550 (1996-10-01), Springer et al.
patent: 5599676 (1997-02-01), Vonderheide et al.
patent: 5612216 (1997-03-01), Springer et al.
patent: 5622700 (1997-04-01), Jardieu et al.
patent: 5629162 (1997-05-01), deFougerolles et al.
patent: 5686265 (1997-11-01), Corbi et al.
patent: 5739032 (1998-04-01), Springer et al.
patent: 5747035 (1998-05-01), Presta et al.
patent: 5821337 (1998-10-01), Carter et al.
patent: 5831036 (1998-11-01), Springer et al.
patent: 5843712 (1998-12-01), Levine
patent: 5849896 (1998-12-01), Springer et al.
patent: 5869046 (1999-02-01), Presta et al.
patent: 5877295 (1999-03-01), Diamond et al.
patent: 5891841 (1999-04-01), deFougerolles et al.
patent: 5914112 (1999-06-01), Bednar et al.
patent: 5948758 (1999-09-01), Springer et al.
patent: 6030947 (2000-02-01), Corbi et al.
patent: 6096871 (2000-08-01), Presta et al.
patent: 6121022 (2000-09-01), Presta et al.
patent: 6121428 (2000-09-01), Blank et al.
patent: 6358510 (2002-03-01), Springer et al.
patent: 6413963 (2002-07-01), Kahn et al.
patent: 6436403 (2002-08-01), Springer et al.
patent: 6511664 (2003-01-01), Springer et al.
patent: 6528698 (2003-03-01), Mizutani et al.
patent: 6572856 (2003-06-01), Taylor et al.
patent: 6683158 (2004-01-01), Springer et al.
patent: 6777191 (2004-08-01), Springer et al.
patent: 6797270 (2004-09-01), Springer et al.
patent: 2001/0031260 (2001-10-01), Lee et al.
patent: 2003/0054440 (2003-03-01), Mayo et al.
patent: 440351 (1991-08-01), None
patent: WO-94/04188 (1994-03-01), None
patent: WO-95/17412 (1995-06-01), None
Burgess, et al. Possible dissociation of the heparin-binding and mitogenic activities of heparin-binding growth factor-1 from its receptor-binding activities by site-directed mutagenesis of a single lysine residue. J Cell Biol. 111:2129-2138, 1990.
Lazar E et al., Transforming growth factor alpha: mutation of aspartic acid 47 and leucine 48 results in different biological activities. Mol Cell Biol. 8:1247-1252, 1988.
Bowie JU, et al Deciphering the message in protein sequences: tolerance to amino acid substitutions. Science. 247(4948):1306-1310, 1990.
Bajt, et al., “Characterization of a gain of function mutation of integrin alpha IIb beta 3 (platelet glycoprotein IIb-IIIa)”,J. Biol. Chem., (1992),267(31):22211-22216.
Bost, et al., “Antibodies against a peptide sequence within the HIV envelope protein crossreacts with human interleukin-2”,Immunol Invest. 17(6-7), (1988),577-86.
Bullard, et al., “A polygenic mouse model of psoriasiform skin disease in CD18-deficient mice”,PNAS, (1996),93:2116-2121.
Champe, et al., “Monoclonal Antibodies That Block the Activity of Leukocyte Function-associated Antigen 1 Recognize Three Discrete Epitopes in the Inserted Domain of CA11a”,J. Bio. Chem., (1995),270(3):1388-1394.
Dickeson, et al., “Ligand recognition by the l domain-containing integrins.”,Cell Mol Life Sci. 54(6), (1998),556-566.
Dransfield, et al., “Divalent Cation Regulation of the Function of the Leukocyte Integrin LFA-1”,J. Cell. Biol., (1992), 116:219-226.
Dransfield, et al., “Interaction of Leukocyte Integrins with Ligand is Necessary but not Sufficient for Function”,J. Cell. Biol., (1992),116:1527-1535.
Fischer, et al., “Prevention of graft failure by an anti-HLFA-1 monoclonal antibody in HLA-mismatched bone-marrow transplantation.”,Lancet. 2(8515), (1986),1058-61.
Hazes, et al., “Model building of disulfide bonds in proteins with known three-dimensional structure.”,Protein Eng. 2(2), (1988),119-125.
Huang, et al., “A Binding Inteface on the I Domain of Lymphocyte Function-associated Antigen-1 (LFA-1) Required for Specific Interaction with Intercellular Adhesion Molecule 1 (ICAM-1)”,J. Biol. Chem., (1995),270:19008-19016.
Huang, et al., “Folding of the beta-propeller domain of the integrin alphaL subunit is independent of the I domain and dependent on the beta2 subunit”,Proc. Natl. Acad. Sci. USA, (1997),94(7):3162-3167.
Huth, et al., “NMR and mutagenesis evidence for an I domain allosteric site that regulates lymphocyte function-associated antigen 1 ligand binding.”,Proc Natl Acad Sci U S A 97(10), (2000),5231-6.
Keizer, et al., “A Monoclonal Antibody (NKI-L16) Cirected against a Unique Epitope on the x-chain of Human Leukocyte Function Associated Antigen I . . . ”,J. Immunol., (1988),140:1393.
Kooyk, et al., “Activation of LFA-1 through the Ca2+-dependent Epitope Stimuatles Lymphocyte Adhesion”,J. Cell. Biol., (1991),112:345-354.
Landis, et al., “A Novel LFA-1 Activation Epitope Maps to the I Domain”,J. Cell. Biol., (1993),120:1519-1527.
Landis, et al., “Involvement of the “I” Domain of the LFA-1 in Selective Binding to the Ligands ICAM-1 and ICAM-3”,J. Cell. Biol., (1994),126:529-537.
Larson, et al., “Primary structure of the leukocyte function-associated moledule-1 alpha subunit: an integrin with an embedded domain defining a protein superfamily”,J. Cell. Biol., (1989),108(2):703-712.
Lee, et al., “Crystal Structure of the A domain from the alpha subunit of integrin CR3 (CD11b/CD18)”,Cell 80(4), (1995),631-8.
Lee, et al., “Two conformations of the integrin A-domain (I-domain):a pathway for activation?”,Structure 3(12), (1995),1333-40.
Leitinger, et al., “The regulation of integrin function by Ca(2+).”,Biochim Biophys Acta. 1498(2-3), (2000),91-98.
Li, Rui , et al., “Two functional states of the CD11b A-domain: correlations with key features of two Mn2+ complexed crystal structures.”,J Cell Biol. 143(6), (1998),1523-34.
Lu, C , et al., “An isolated, surface-expressed I domain of the integrin alphaLbeta2 is sufficient for strong adhesive function when locked in the open conformation with a disulfide bond.”,Proc Natl Acad Sci U S A 98(5), (2001),2387-92.
Lu, et al., “Locking in alternate conformations of the integrin alphaLbeta2 I domain with disulfide bonds reveals functional relationships among integrin domains”,Proc. Natl. Acad. Sci. USA, (2001),98(5):2393-2398.
Morimoto, et al., “A novel epitope of the LFA-1 antigen which can distinguish killer affector and supressor cells in human CD8 cells.”,Nature. 330(6147), (1987),479-82.
“National PBM Drug Monograph Efalizumab”, www.vapbm.org, (2004),1-25.
Ohashi, et al., “Three monoclonal antibodies against human LFA-1 alpha and beta chains with different biological activities.”,Tohoku J Exp Med. 168(4), (1992),599-610.
Orchekowski, et al. “AlphaMbeta2 (CD11b/CD18, Mac-1) integrin activation by a unique monoclonal antibody to alphaM I domain that is divalent cation-sensitive.”,J Leukoc Biol. 68(5), (2000),641-9.
Owens, et al., “The genetic engineering of monoclonal antibodies.”,J Immunol Methods 168(2), (1994), 149
Lu Chafen
Shimaoka Motomu
Springer Timothy A.
Center for Blood Research, Inc.
Gosz & Partners LLP
Haddad Maher M.
LandOfFree
Modified polypeptides stabilized in a desired conformation... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modified polypeptides stabilized in a desired conformation..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified polypeptides stabilized in a desired conformation... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3733437